Although the FDA has approved Resmetirom as a new treatment option, 661 lifestyle interventions targeting NAFLD/NASH risk factors, such as weight loss through a healthy diet and physical activity, are expected to remain central to improving patient outcomes
This therapy can boost immune function, improve circulation, and support overall wellness
Always feel free to consult your healthcare provider if you have any concerns
Clinical data shows that nausea affects between 2030% of semaglutide users, making it one of the most common early side effects
The metabolomics profiles of severe COVID-19 patients and patients with advanced cancer are similar, and in high-risk patients, SARS-CoV-2 infection leads to aberrant STAT3 activation, which promotes a cancer-like metabolism